课题基金 / 基金详情

项目摘要

项目成果

Diana Blithe的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The research project has a goal to develop novel male contraceptive agents. Candidate drugs have been developed and have been submitted for patents through an employee invention report. This class of steroid core molecules could be a first-in-class male contraceptive agent that possesses all necessary hormonal properties for which serum testosterone is responsible. Lead candidates are derivitized to prepare pro-drugs that can sustain the androgenic activity for 24 hours for oral or transdermal gel, patch or aerosol formulations or could provide extended activity over several months when administered as an injection, implant, microneedle array or other delivery method for the purpose of male contraception or potential endocrine therapies. As a male contraceptive agent, this invention takes advantage of molecules with demonstrated androgenic activity, oral bioavailability and combines modifications that maintain drug levels over a sustained period so that oral dosing is limited to one dose per day. Thus, one molecule contains multiple hormonal activities that fulfill all necessary hormonal activities for which serum testosterone is required but does not support testicular function that would lead to spermatogenesis. Several lead candidates are being evaluated for receptor binding and transactivation properties that demonstrate the desired functional activities of the drug. Since the products, if successful in achieving the desired functions, would have commercial utility, publications cannot be issued until after patent applications have been filed through appropriate channels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of novel contraceptive methods for men and women
Development of novel contraceptive methods for men and women
Development of novel contraceptive methods for men and women
Novel Substituted Steroid Hormones
海外基金